Form 8-K - Current report:
SEC Accession No. 0001193125-24-161572
Filing Date
2024-06-14
Accepted
2024-06-14 16:01:03
Documents
13
Period of Report
2024-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d788157d8k.htm   iXBRL 8-K 30230
  Complete submission text file 0001193125-24-161572.txt   156501

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nmra-20240613.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20240613_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20240613_pre.xml EX-101.PRE 11712
16 EXTRACTED XBRL INSTANCE DOCUMENT d788157d8k_htm.xml XML 3769
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 241044592
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)